MGC 026
Alternative Names: MGC-026Latest Information Update: 26 Dec 2025
At a glance
- Originator MacroGenics
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 Oct 2025 Pharmacodynamics data from a preclinical trial in Castration-resistant prostate cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 09 May 2024 Pharmacodynamics data from a preclinical trial in Solid tumour released by MacroGenics
- 05 Apr 2024 Adverse events, pharmacodynamics and pharmacokinetics data from a preclinical studies in Solid tumour wre presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)